Complement Therapeutics announces the closing of a 72 million € Series A financing round led by Gimv together with existing investor Forbion and further joined by BioGeneration Ventures (BGV), Panakes Partners, Cambridge Innovation Capital (CIC), Hadean Ventures and Seroba Life Sciences. Complement Therapeutics will use the proceeds of this round to continue to develop its innovative therapies for the treatment of complement-related diseases, with particular focus on ophtalmology.

Complement Therapeutics, a spin-out of the University of Manchester founded in 2021, aims to transform the treatment of complement-mediated conditions by developing novel therapies such as CTx001, an innovative AAV gene therapy for the treatment of geographic atrophy, a progressive and advanced form of age-related macular degeneration (AMD) associated with significant, irreversible loss of vision.

Furthermore, the financing round will allow Complement Therapeutics to evaluate its pipeline assets for non-ocular indications as well as further develop the novel Complement Precision Medicine (CPM) platform.

Michaël Vlemmix, Principal Life Sciences at Gimv and Board Director at CTx comments: “One of the pillars of our Life Sciences strategy is to invest in companies where cutting-edge science could lead to a potential paradigm shift in the treatment and lives of patients.  Complement Therapeutics is a key example of such an investment whereby we are proud to have been able to build a strong syndicate, supported by a high-quality current investor base.”

Rishabh Chawla, Associate of Gimv’s Life Sciences team and Observer at CTx adds:“With the ability to target the etiology of complement-related diseases along with a very experienced and dedicated management team, we are convinced that Complement Therapeutics will make a real difference to patients that have limited treatment options today.”

For more information, please read the full press release from Complement Therapeutics attached.